[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Miami\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":586},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,156,0,25,[9,44,68,93,114,148,179,203,226,250,269,287,306,330,353,374,396,419,440,464,484,506,527,549,567],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645864","active-versus-passive-sitting-cognition-and-energy-100645864",false,"NCT07699848","Active Versus Passive Sitting, Cognition and Energy","Differences in Muscle Utilization, Tissue Pressure, Cognitive Performance, and Caloric Output Among Active and Passive Sitting Positions.","Inclusion Criteria:\n\n* Adult (18-70)\n\nExclusion Criteria:\n\n* Any current injury in the lower limb or trunk.\n* Use of prescription drugs or supplements that may affect cardiovascular or neuromuscular responses.\n* Reported lack of sleep or stress that may affect physiological responses to exercise.\n* Cardiovascular, respiratory, neurologic, balance, metabolic, or musculoskeletal conditions that could increase risk during exercise testing",true,"ALL","18 Years","70 Years",{"count":22,"type":23},35,"ESTIMATED","INTERVENTIONAL",[26],"NA","The study will compare cognitive capacity, muscle utilization patterns, soft tissue seated pressure and caloric output during four seated conditions:\n\n1. passive sitting in a regular chair;\n2. passive sitting in an exercise chair;\n3. sitting in the exercise chair during active dynamic exercise; and,\n4. sitting in the chair during active static exercise.",[29,30],"Electromyography","Pressure Injury of Back","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":35},"2026-06-23",{"date":39,"type":23},"2027-09-30",{"name":41,"class":42},"University of Miami","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100631468","phase-4-prophylactic-antibiotics-for-outpatient-urethral-bulking-100631468","NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at the University of Miami with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-procedural work-up, including either negative urine culture or urine dip negative for infection (infection is defined as the presence of nitrites and\u002For pyuria with \\>1+ leukocyte esterase on dipstick or \\>5 WBC\u002FHPF).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan) before the procedure\n* Fluent in English or Spanish\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease (GFR \\\u003C30)\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly that also involve insertion \\[KB2.1\\]of a foreign object\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Patients with immunosuppression due to underlying medical conditions\n* Patients who are pregnant\n* Recent antibiotic treatment within one week of the procedure\n* Unable or unwilling to provide informed consent or complete study procedures","FEMALE",{"count":53,"type":23},150,[55],"PHASE4","The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).",[58,59,60],"Urinary Tract Infections","Stress Urinary Incontinence","Urinary Incontinence",{"date":34,"type":35},{"date":63,"type":23},"2026-08",{"date":65,"type":23},"2028-12",{"name":41,"class":42},2,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":74,"minAge":19,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":24,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100613166","prep--soccer-a-program-for-pharmacy-chains-to-increase-prep-awareness-and-access-among-men-100613166","NCT07263048","PrEP & Soccer: A Program for Pharmacy Chains to Increase PrEP Awareness and Access Among Men","Inclusion Criteria:\n\n* Provide their informed consent to participate.\n* Demonstrate willingness to comply with all study procedures and be available for the study duration.\n* Ages 18 to 54 years of age.\n* A man.\n* Self-report any of the following behaviors and\u002For health conditions\n\n  1. Diagnosed with bacterial sexually transmitted infection (e.g., syphilis, gonorrhea, or chlamydia)\n  2. Sex with a partner who is living with HIV\n  3. Sex without a condom with two or more partners whose HIV status were unknown\n  4. Injection drug use and sharing injection equipment\n* Have been without a PrEP prescription for at least 24 weeks.\n\nExclusion Criteria:\n\n* Diminished capacity to consent due to:\n\n  1. Inability to provide informed consent (e.g., cognitive impairment), or\n  2. Presence of severe psychiatric symptoms (e.g., mania, psychosis) that impair the ability to provide informed consent, as assessed by interviewers trained in CITI Human Subjects Research and NIH Good Clinical Practice.\n* Younger than 18 or older than 54 years of age.\n* A woman.\n* Does not self-report any of the following behaviors and\u002For health conditions\n\n  1. Diagnosed with bacterial sexually transmitted infection (e.g., syphilis, gonorrhea, or chlamydia)\n  2. Sex with a partner who is living with HIV\n  3. Sex without a condom with two or more partners whose HIV status were unknown\n  4. Injection drug use and sharing injection equipment\n* Has had an active PrEP prescription within the past 24 weeks.\n* Living with HIV (e.g. has received an HIV diagnosis).\n* Planning to move outside of Miami-Dade or Broward counties in the next 7 months.","MALE","54 Years",{"count":77,"type":23},800,[26],"This type 3 Hybrid Effectiveness-Implementation study will evaluate PrEP \\& Soccer, a multicomponent and multilevel implementation strategy delivered by a pharmacy chain to increase PrEP knowledge and initial PrEP appointment attendance among men. Using mixed methods and implementation science approaches, this parallel cluster randomized controlled study will assess key implementation factors at CVS Health pharmacy locations assigned either to the PrEP \\& Soccer intervention or to a general CVS Health service information-only control.",[81,82,83],"HIV Prevention","Latino Men Who Have Sex With Men","Pharmacy","NOT_YET_RECRUITING","2026-08-17",{"date":87,"type":35},"2026-08-19",{"date":89,"type":23},"2026-10-30",{"date":91,"type":23},"2029-10",{"name":41,"class":42},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":43},"100597522","preoperative-comprehensive-geriatric-assessment-cga-and-postoperative-delirium-100597522","NCT07059585","Preoperative Comprehensive Geriatric Assessment (CGA) and Postoperative Delirium","Does Perioperative Comprehensive Geriatric Assessment Reduce the Incidence of Postoperative Delirium in Older, Frail Patients Undergoing Elective Inpatient Surgery?","Inclusion Criteria:\n\n1. Frailty as measured by the 5-modified frailty index (5-mFI) during the anesthesia preoperative assessment. The 5-mFI consists of 5 elements: 1-dependency for activities of daily living, 2-congestive heart failure within 30 days, 3-chronic obstructive pulmonary disease or pneumonia currently treated with antibiotics, 4-diabetes, and 5-hypertension. The diagnosis of frailty by the 5-mFI is based upon the presence of 2 or more of the elements.\n2. Elective inpatient surgery with an expected LOS \\> 1 day;\n3. Receiving general anesthesia\n4. Adults who are unable to consent if they have a designated proxy able to consent\n\nExclusion Criteria:\n\n1. Absence or withdrawal of informed consent,\n2. Presence of current delirium\n3. prisoners","60 Years",{"count":102,"type":23},200,[26],"The purpose of this research is to find out the best way to reduce delirium in frail, older patients undergoing planned surgery. Delirium is a state of confusion and difficulty concentrating that is temporary. Delirium may make the person anxious, angry, sleepy, not think clearly, or hallucinate. Being frail in medicine means that the body may not easily recover from a stressor, such as surgery. This study will determine if a detailed on-going evaluation by a Geriatrician, doctor who specializes in the care of older adults, after surgery is better at decreasing the risk of delirium than simply highlighting the patient's frailty in the electronic medical record.",[106],"CGA","2026-08-14",{"date":32,"type":35},{"date":110,"type":35},"2025-07-29",{"date":112,"type":23},"2026-12-31",{"name":41,"class":42},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":17,"sex":18,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100471990","mental-health-in-primary-care-100471990","NCT05426057","Mental Health in Primary Care","Scaling a Parenting Evidence Based Intervention (EBI) for Latinx Youth Mental Health in Primary Care","Inclusion Criteria:\n\n1. Female and male adolescents, who self-identify as Hispanic (or Latino(a))\n2. Adolescent between the ages of 12 - 16 years\n3. Adolescent living with an adult primary caregiver who is willing to participate\n4. Families must have broadband internet access on a device, including (but not limited to) a smartphone, iPad, tablet, computer at their home or other location (e.g., school, library, etc.)\n5. Families screening positive on poor family communication (a score of less than 75 on the communication measure; see measures) or youth reporting elevated depressive or anxiety symptom scores (defined as 70 to 90 on the K-CAT) or a history of suicide behavior (ideation or attempts).\n\nExclusion Criteria:\n\n* Families reporting plans to move out of the South Florida area during the study period.","12 Years","16 Years",{"count":124,"type":23},468,[26],"The goal of this study is to evaluate in an effectiveness-implementation type I hybrid trial, an enhanced version of eHealth Familias Unidas for reducing depressive, anxious symptoms and suicide behavior in Hispanic youth. The study will use a randomized rollout design with 18 pediatric primary care clinics in the South Florida area.",[128,129,130],"Depression, Anxiety","Suicide","Drug Use",[132,133,134,135,136,137,138,139,140],"effectiveness-implementation type 1 hybrid trial","Latinx mental health in primary care","Latinx adolescent","eHealth intervention","Familias Unidas","intervention sustainment","parent-centered","family functioning","sexual risk behavior",{"date":32,"type":35},{"date":143,"type":35},"2022-04-26",{"date":145,"type":23},"2028-04-30",{"name":41,"class":42},17,{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100617408","adaptive-self-efficacy-based-ai-coaching-for-cycling-100617408","NCT07318233","Adaptive Self-Efficacy-Based AI Coaching for Cycling","Adaptive Self-Efficacy-Based AI Coaching for Enhanced Indoor Cycling Performance: A Personalized Machine Learning Approach","AI","Inclusion Criteria:\n\n* Age 18-40 years\n\n  * Recreationally active\n  * Familiar with stationary cycling\n  * Able to complete 20 minutes of vigorous cycling\n\nExclusion Criteria:\n\n* Cardiovascular, metabolic, or respiratory conditions\n\n  * Medications affecting heart rate response\n  * Lower extremity injury within past 3 months\n  * Competitive cyclists (\\>10 hours cycling\u002Fweek)\n  * Pregnancy","40 Years",{"count":158,"type":23},120,[26],"The primary objective of this study is to evaluate whether adaptive, AI-delivered personalized self-efficacy-based AI coaching based on real-time physiological and performance feedback enhance indoor cycling power output during a 20-minute time trial compared to static affirmations and exercise-only control conditions.",[162,163,164,165,166],"Exercise Training","Exercise Behavior","Exercise Adherence Challenges","Motivation for Physical Activity","Motivational Enhancement",[168,169,170,171],"Physical Activity","AI affirmations","just-in-time adaptive intervention","cycling","2026-08-13",{"date":85,"type":35},{"date":175,"type":35},"2026-05-15",{"date":177,"type":23},"2028-12-28",{"name":41,"class":42},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":17,"sex":18,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":24,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":202,"locationsCount":67},"100609028","haptics-in-virtual-reality-100609028","NCT07209228","Haptics in Virtual Reality","Investigating the Role of Haptic Feedback in Virtual Reality Learning Environments for Literacy Acquisition","Inclusion Criteria:\n\n* Students from elementary to higher education;\n* Students aged 6 years old and up.\n\nExclusion Criteria:\n\n* Students with significant uncorrected vision;\n* Students with significant hearing impairments;\n* Students with severe cognitive conditions;\n* Students with significant neurological conditions;\n* Students with significant motor conditions that would prevent safe participation in a VR-based learning activity.","6 Years",{"count":188,"type":23},60,[26],"The purpose of this study is to investigate the role of non-invasive wearable haptic feedback, in supporting literacy-focused Virtual Reality (VR) learning environments. The haptic feedback will be delivered through haptic gloves with integrated vibration monitors and finger tracking. The primary objective is to examine how multisensory engagement, specifically the addition of haptic cues, influences learning outcomes such as phonetic recognition, spelling, and reading skills in early learners.",[192,193,194],"Literacy","Literacy-language Intervention","Haptics",[196,192,194,197],"Virtual Reality","Education",{"date":85,"type":35},{"date":200,"type":23},"2026-12-01",{"date":177,"type":23},{"name":41,"class":42},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":17,"sex":18,"minAge":186,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":67},"100606054","relationship-enhancement-digital-game-100606054","NCT07170553","Relationship Enhancement Digital Game","Digital Game Intervention for Relationship Enhancement Among Parent Child Dyads","Inclusion Criteria:\n\n* Caregiver-child dyads.\n\nExclusion Criteria:\n\n* Participant is not part of a caregiver- child dyad.",{"count":211,"type":23},30,[26],"The purpose of this study is to test a new digital game. Specifically, this study will aim to evaluate a digital game prototype designed to facilitate playful interactions between parents and children. The prototype will incorporate activities grounded in relationship enhancement principles. Additionally, this study will check how well using digital tools helps build strong connections, makes people get along better, and boosts parents' confidence and parenting skills.",[215,216,217],"Parent-Child Relations","Parenting","Attachment Disorder",[219,220],"Digital Intervention","Attachment Based",{"date":85,"type":35},{"date":175,"type":35},{"date":224,"type":23},"2027-04-30",{"name":41,"class":42},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":74,"minAge":19,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":43},"100512866","reset-for-the-treatment-of-stimulant-use-in-hiv-clinics-care-optimization-supporting-treatment-adherence-costa-100512866","NCT05958017","reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)","COSTA","Inclusion Criteria:\n\n1. Assigned male sex at birth and has not undergone any transgender hormonal treatment\n2. Reports having had sex with a male in the past 12 months\n3. Age 18 or older\n4. Is affiliated with a study referral source (e.g., AHF clinic, registry, other healthcare program or clinic) or resides in a city or county where a participating healthcare center or health program is located\n5. Screens positive for mild, moderate or severe stimulant use disorder in the last 12 months using the MINI\n6. Reports that he is not currently in drug treatment\n7. Is living with HIV\n8. Reports having an active antiretroviral prescription\n9. Have access to a smartphone or tablet with stable internet at least twice a week and can download applications to the smartphone or tablet\n10. Able to understand English\n11. Consents to participation in the study\n12. Provides sufficient locator information\n13. Identifies as non-Hispanic White, non-Hispanic Black\u002FAfrican American or Latinx\u002FHispanic\n14. Has been in stable housing for the past 3 months and intends to remain housed for the next 15 months\n\nExclusion Criteria:\n\n1. Patient appears to have diminished capacity to consent either because of cognitive impairment or severe psychiatric symptoms (e.g., mania, psychosis).\n2. Persons that meet criteria for prisoner status will be excluded at baseline.\n3. Patients who screen positive for moderate to severe opioid use disorder will be excluded from the study because effective pharmacological agents exist for the treatment of this disorder. These patients will be referred to community-based programs that provide specialized treatment for this disorder.\n4. Participants will be excluded prior to randomization, if they do not complete at baseline the Time-Line Follow-Back or the laboratory visit.","90 Years",{"count":235,"type":23},260,[26],"The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.",[239,240],"Stimulant Use Disorder","People Living With HIV",[242,243],"Substance use","Adherence to Anti-Retroviral Therapy",{"date":85,"type":35},{"date":246,"type":35},"2025-03-04",{"date":248,"type":23},"2028-01-31",{"name":41,"class":42},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":24,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":43},"100559989","family-sleep-program-100559989","NCT06571305","FAMILY Sleep Program","Inclusion Criteria:\n\n* The eligibility criteria for patients are\n\n  * newly diagnosed with stage I to IV of a solid tumor\n  * diagnosis in the past seven years at the time of enrollment\n  * having a consistent sleep partner.\n* The eligibility criterion for caregivers is\n\n  * a sleep partner of the patient.\n* Additional eligibility criteria for both patients and caregivers are\n\n  * Pittsburgh Sleep Quality Index (PSQI) ≥ 5,\n  * willing to change sub-optimal sleep habits,\n  * 18 years or older,\n  * able to speak\u002Flisten English at the 8th grade level for intervention sessions,\n  * able to read English or Spanish at the 8th grade for self-reported questionnaires, reside in Brevard County, Florida (FL),\n  * only for participants of Aim 2, \\> 4 weeks after surgery, if any, prior to enrollment, and no surgery planned in the next 5 weeks during the study period because surgery affects sleep.\n\nExclusion Criteria:\n\n* Exclusion criteria for both patients and caregivers are:\n\n  * having had a diagnosis of major depressive disorder, psychosis, or bipolar disorder that is not currently treated;\n  * active suicidality, or substance or alcohol dependency in the past year;\n  * currently have narcolepsy, restless leg syndrome, or untreated sleep apnea that is screened using the Sleep Health Screen;\n  * both patients and caregivers have an extreme chronotype, or do shift work to have no overlap in sleep schedule between them; and\n  * plan trans-meridian travel during the period of data collection blocks; and\n  * having hearing or visual impairment, dementia, or cognitive dysfunction.\n* Adults unable to consent, individuals who are not yet adults, pregnant women, or prisoners will be excluded.",{"count":257,"type":23},18,[26],"The purpose of this study is to learn about sleep behaviors and test different ways to help patients with cancer and partners. Participants (patient-sleep-partner caregivers dyads as a unit) participate in the study together.",[261],"Cancer","2026-08-12",{"date":107,"type":35},{"date":265,"type":35},"2024-08-01",{"date":267,"type":23},"2027-10-01",{"name":41,"class":42},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":43},"100547352","brain-controlled-spinal-stimulation-walking-therapy-after-incomplete-spinal-cord-injury-sci-100547352","NCT06406855","Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI)","Brain-Controlled Spinal Stimulation Therapy for Restoration of Walking After Incomplete Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n1. At least 18 years old and no older than 70 years old at the time of enrollment.\n2. Traumatic incomplete spinal cord injury (neurological level at or above T10 spinal cord level; Abbreviated Injury Scale (AIS) C or D impairment grade for group 1, 3 and 4 and AIS B, C or D impairment grade for group 2), who are more than 6 months post-injury.\n3. Has detectable motor function in at least 2 muscles per side confirmed by voluntary Electromyography (EMG) or detectable tibialis anterior (TA) muscle motor evoked potentials (MEPs) at the baseline assessment.\n4. Able to commit to intensive training and assessment sessions over a maximum total duration of 6 months.\n5. Could effectively walk overground for at least 10 meters with some assistance of a therapist and minimal body-weight support, with functional spasticity (by participant's self-report), functional range-of-motion of lower limb joints, and acceptable bone mass to enable body-weight support, confirmed by Dual-energy X-ray absorptiometry (DXA) scan.\n\nExclusion Criteria:\n\n1. Has traumatic brain injury, stroke, multiple sclerosis, or other neuromuscular disorders that could affect neuromotor function and walking.\n2. Has severe spasticity that could prevent stepping and walking function determined by the investigator.\n3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.\n4. Has other contra-indications for transcranial magnetic stimulation (TMS) or Transcutaneous Spinal Cord Stimulation (TSCS).\n5. Has a history of recent seizures or poorly managed autonomic dysreflexia that could be triggered by TMS or TSCS.\n6. Has a history of prior intracranial surgery or known lesions that would limit TMS assessments and Brain-Computer Interface (BCI) recordings.\n7. Individuals with metal implants in their head and other implantable devices in the body that could be affected by TMS or TSCS.\n8. Has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).\n9. Has urinary tract infection, unhealed fracture, contracture, and pressure sore (Braden Scale).\n10. Has breakdown in skin area that will come into contact with electrodes.\n11. Individuals who require therapy or other care that could interfere with participation in the study.\n12. Individuals on investigational drugs or any other intervention known to have a potential impact on neuromotor function.\n13. Individuals with substance disorders, including alcoholism and drug abuse.\n14. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.\n15. In the opinion of the investigators, the study is not safe or appropriate for the participant.",{"count":277,"type":23},12,[26],"The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).",[281],"Spinal Cord Injuries",{"date":107,"type":35},{"date":284,"type":35},"2024-05-07",{"date":112,"type":23},{"name":41,"class":42},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":296,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":305,"locationsCount":43},"100538627","phase-2-understanding-and-treating-traumatic-brain-injury-tbi-associated-photophobia-with-botulinum-toxin-type-a-bont-a-100538627","NCT06293300","Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)","Understanding and Treating TBI Associated Photophobia With Botulinum Toxin Type A and Its Impact on Visual Function","Inclusion Criteria:\n\n* Recruit and enroll male and female subjects, civilians and veterans (1:1 mix anticipated, i.e., n = 25 from each group) of all races and ethnicities.\n* ≥18 years of age who are able to consent.\n* Report chronic photophobia (Numerical Rating Scale ≥4 on a 0-10 scale, photophobia present ≥6 months) with a remote history of TBI (\\>1 year).\n* Inclusion into the study with regard to TBI status will be based on the Department of Defense Standard Surveillance Case Definition for TBI Adapted for Armed Forces Health Surveillance Division (AFHSB) Use. This can include one hospitalization or outpatient medical encounter with documented International Classification of Diseases (ICD9\u002FICD10) codes as identified within the Surveillance Case Definition.\n* Subjects must also have been on a stable medication regimen for the past 3 months and must be naïve to BoNT-A treatment for orofacial conditions.\n* English as primary language (by self-report).\n\nExclusion Criteria:\n\n* Individuals with ocular diseases that may confound photophobia, such as glaucoma, corneal and conjunctival scarring, corneal edema, uveitis, iris transillumination defects, retinal degeneration, etc.\n* Patients who are participating in another study with an investigational drug within one month prior to screening.\n* Pregnant individuals. Pregnant subjects will not be scanned in the functional Magnetic Resonance Imaging (fMRI). Although there are no known risks associated with MRI during pregnancy, according to facility policy, University of Miami will not scan someone that is pregnant. Therefore, all women of childbearing potential (menstruating or \\>12 years old) must complete a for stating that are not pregnant within 24 hours of each MRI scan.\n* Individuals with contraindications to fMRI scanning (e.g. metal implants, pacemaker) will not be offered inclusion.",{"count":295,"type":23},50,[297],"PHASE2","The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.",[300],"Traumatic Brain Injury",{"date":107,"type":35},{"date":303,"type":35},"2024-09-30",{"date":39,"type":23},{"name":41,"class":42},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":17,"sex":74,"minAge":19,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":317,"phases":4,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":43},"100168574","male-fertility-program-100168574","NCT01467869","Male Fertility Program","The Miami Project Male Fertility Program","MFP","Inclusion Criteria:\n\n* Any man with spinal cord injury over the age of 18. Control Subjects will be any healthy man over the age of 18 with no recent history of infertility\n\nExclusion Criteria:\n\n* Women will be excluded.","50 Years",{"count":316,"type":23},100,"OBSERVATIONAL","Following spinal cord injury, most men are infertile and require medical assistance to father children. The conditions that contribute to their infertility are erectile dysfunction, ejaculatory dysfunction, and semen abnormalities. The Miami Project Male Fertility Program is a research study designed to understand and improve impairments to male fertility resulting from spinal cord injury.",[320],"Spinal Cord Injury",[322,323],"abnormal semen","assisted conception",{"date":85,"type":35},{"date":326,"type":35},"1991-01",{"date":328,"type":23},"2040-12",{"name":41,"class":42},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":43},"100629049","ehealth-mindfulness-based-music-therapy-intervention-for-patients-undergoing-stem-cell-transplantation-100629049","NCT07469592","eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation","Inclusion Criteria:\n\n* ≥ 18 years of age\n* have a primary diagnosis of a hematologic malignancy (e.g., myelodysplastic syndrome \\[MDS\\], acute myeloid leukemia \\[AML\\], acute lymphoblastic leukemia \\[ALL\\], or non Hodgkin's Lymphoma \\[NHL\\])\n* have a treatment plan for a hematopoietic stem cell transplant\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)\n* severe cognitive impairment (per the short portable mental status questionnaire)\n* hearing impairment\n* active alcohol or substance dependence within the past six months\n* participated in the prior pilot MBMT R61 phase\n* participated in music therapy or mindfulness programs in the past six months",{"count":337,"type":23},165,[26],"The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem cell transplantation.",[341,342,343,344,345],"Stem Cell Transplantation","Myelodysplastic Syndromes","Leukemia, Myeloid, Acute","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Lymphoma, Non-Hodgkin","2026-08-11",{"date":172,"type":35},{"date":349,"type":35},"2026-07-22",{"date":351,"type":23},"2028-06-30",{"name":41,"class":42},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":43},"100630935","phase-4-dose-dependent-steroid-injections-100630935","NCT07494136","Dose Dependent Steroid Injections","Dose Dependent Response to Interlaminar Steroid Injections for Lumbar Radiculopathy","Inclusion Criteria:\n\n* Adults able to consent\n* Lumbar radiculopathy with MRI-confirmed pathology\n* No history of back surgery\n* Use of interlaminar approach lumbar spine injections\n* No use of oral pain medication other than Tylenol or Acetaminophen during the 6 weeks after injection\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* History of back surgery\n* Use of oral pain meds other than Tylenol or Acetaminophen during the 6 weeks after injection",{"count":53,"type":23},[55],"This study aims to evaluate the efficacy of interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, to evaluate the efficacy of interlaminar steroid injections at improving quality of life and function in lumbar radiculopathy at varying doses, and to evaluate difference in efficacy between triamcinolone and dexamethasone interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, with the overarching hypotheses that there is no difference in reported pain reduction, quality of life, or function among patients receiving low, moderate, or high doses, and no difference in reported pain reduction between triamcinolone and dexamethasone.",[364,365,366],"Lumbar Radiculopathy","Sciatica","Back Pain With Radiation","2026-08-10",{"date":262,"type":35},{"date":370,"type":23},"2026-09-15",{"date":372,"type":23},"2027-05",{"name":41,"class":42},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100547757","phase-4-study-evaluating-safety-tolerability-and-metabolism-of-niraparib-100547757","NCT06412120","Study Evaluating Safety, Tolerability, and Metabolism of Niraparib","Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry","Inclusion Criteria:\n\n1. Participant must be female ≥18 years of age, able to understand study procedures, and agree to participate in the study by providing written informed consent.\n2. Self-identify as Black. Please note that individuals who identify as Latino are eligible to participate so long as they also self-identify as Black.\n3. Participant has completed adjuvant treatment for newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer according to the International Federation of Gynecology and Obstetrics staging criteria.\n4. Participant must have high-grade serous or high-grade endometrioid histology.\n5. Participant must provide saliva and\u002For blood specimens for assessment of germline mutation(s) in the Fanconi Anemia pathway.\n6. Participant must provide formalin-fixed, paraffin-embedded (FFPE) or fresh tumor specimen from initial cytoreductive surgery (primary debulking) or initial pre-treatment core biopsy (if neoadjuvant chemotherapy (NACT) received; tumor obtained from interval cytoreduction acceptable if pre-treatment biopsy not obtained).\n7. Participant must have had a complete or partial clinical response to adjuvant treatment as confirmed by CT scan within 8 weeks after completion of the last dose of platinum-based chemotherapy.\n8. Participant must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments.\n9. Participant must not have any known contraindication or hypersensitivity to niraparib or any of its excipients.\n10. Participants must be considered candidates for maintenance niraparib therapy by their treating physician.\n11. Participants should have adequate organ function as defined below:\n\n    * Platelets ≥ 100 platelets × 10\\^9\u002FL\n    * Hemoglobin ≥ 9 g\u002FdL or 5.6 mmol\u002FL\n    * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN), \\\u003C5× in patients with known liver metastases\n    * Serum total bilirubin ≤ 1.5 × ULN\n    * 1.5-3.0 × ULN may be included with appropriate starting dose adjustment to 200 mg daily.\n    * Creatinine \\\u003C1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥50 mL\u002Fmin by Cockcroft-Gault\n\n      * Depending on scenario, glomerular filtration rate (GFR) 30-49 mL\u002Fmin can be permissible.\n12. Patients with known human immunodeficiency virus (HIV) are allowed if they meet all the following criteria:\n\n    * Cluster of differentiation 4 (CD4) ≥350\u002FμL and viral load \\\u003C400 copies\u002FmL\n    * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months before enrollment\n    * No history of HIV-associated malignancy for the past 5 years. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started \\>4 weeks before study enrollment.\n13. A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:\n\n    * Is not a woman of childbearing potential (WOCBP), or\n    * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year) from the Screening Visit through at least 180 days after the last dose of study treatment and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment, and\n    * A WOCBP must have a negative test result from a highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before treatment. Additional periodic testing should be carried out according to the protocol.\n\n    Note: The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n14. Participant must agree to complete HRQoL and patient reported outcomes (PRO) measures throughout the study period.\n\nExclusion Criteria:\n\n1. Any of the following histologies: low-grade serous carcinoma, grade 1 or 2 endometrioid adenocarcinoma, clear cell, mucinous, transitional cell, carcinosarcoma, undifferentiated, dedifferentiated\n2. Any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n3. Primary progressive, platinum-refractory disease\n4. Participant is at an increased risk of bleeding due to concurrent conditions (eg, major injuries or major surgery within the past 28 days before start of study treatment).\n5. Current diagnosis of platelet disorder (eg, thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP))\n6. Inability to swallow orally administered medication or has a gastrointestinal disorder likely to interfere with absorption of the study medication\n7. Participants that have systolic blood pressure (SBP\\])\\>140 mmHg or diastolic blood pressure (DBP)\\>90 mmHg that has not been adequately treated or controlled.\n8. Active second primary malignancy\n9. Participant is pregnant, currently breastfeeding an infant, or expecting to conceive children while receiving study treatment and\u002For for up to 180 days after the last dose of study treatment.\n10. Participant has received a live vaccine within 30 days of planned start of study therapy. Coronavirus disease 2019 (COVID-19) vaccines that do not contain live viruses are allowed.\n11. Participant has received a transfusion (platelets or red blood cells) or colony-stimulating factors (eg, granulocyte macrophage colony-stimulating factor or recombinant erythropoietin) within 4 weeks before the first dose of study treatment.\n12. Participant has had radiotherapy encompassing \\>20% of the bone marrow within 2 weeks or any radiation therapy within 1 week before Day 1 of protocol therapy.\n13. Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastasis, or radiographic signs of central nervous system hemorrhage.\n14. Participant has current active pneumonitis or any history of pneumonitis requiring steroids (any dose) or immunomodulatory treatment within 90 days of planned start of the study.\n15. Participants with active hepatitis B or C infection.\n16. Patient with prior history of posterior reversible encephalopathy syndrome (PRES).\n17. Patients with impaired decision-making capacity.\n18. Participants have high medical risk due to a serious, uncontrolled medical disorder; non malignant systemic disease; or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent.\n19. Patient is currently receiving one or more cytotoxic, hormonal, or other medications to treat their cancer.",{"count":382,"type":23},70,[55],"The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigational medication called niraparib is being tested for the treatment of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their genes. Cancer cells with damaged genes have a harder time growing and spreading in the body and can even die.",[386],"Ovarian Cancer","2026-08-03",{"date":389,"type":35},"2026-08-05",{"date":391,"type":35},"2026-07-28",{"date":393,"type":23},"2031-07-28",{"name":41,"class":42},4,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":24,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":43},"100522013","miami-radar-trial-100522013","NCT06077071","Miami \"RADAR\" Trial","The Miami \"RADAR\" Trial - RAdiosurgical Debulking of Asymptomatic\u002FRadiographic Spinal Cord Compression","RADAR","Inclusion Criteria:\n\n1. Male and female participants ages ≥ 18.\n2. Solid tumors causing Metastatic epidural spinal cord compression (MESCC) for which surgery is an option as first-line treatment.\n3. Tumor histologies eligible for treatment include breast, prostate, sarcoma, melanoma, gastrointestinal types, NSCLC and renal cancers. Other solid malignancy types are also allowed at discretion of investigator if not specifically excluded by criteria.\n4. MRI of involved spine within 4 weeks prior to registration to determine extent of spine involvement.\n5. Bilsky scale ≥ 1c MESCC with tumor ≤ 1 mm from the spinal cord or cauda equina nerve roots anywhere from C1 to terminus of cauda equina on screening MRI.\n6. Protocol defined MESCC must involve no more than 3 contiguous vertebral levels. MESCC can involve multiple non-contiguous spinal canal regions within those 3 contiguous vertebral levels.\n7. Karnofsky performance score ≥60\n8. Survival prognosis ≥3 months\n9. Medical status allowing surgery.\n10. Neurologic exam within 1 week prior to registration and again within 1 week of first treatment to rule out severe neurologic deficits caused by disease at site of cord compression.\n11. Patients with mild to moderate cord neurologic signs are eligible if they are improved or stabilized by steroid. These neurologic signs include radiculopathy, dermatomal sensory change, and muscle strength of involved extremity 4\u002F5 (lower extremity for ambulation or upper extremity for raising arms and\u002For arm function).\n12. All patients must be ambulatory.\n13. Numerical Rating Pain Scale within 1 week prior to registration (back pain permitted for enrollment).\n14. Spine instability neoplastic score \\\u003C 14.\n\n    a. An exception to this criterion may be made if the patient is evaluated by a spinal surgeon and the surgeon defers surgery.\n15. Willing and able to undergo daily MRI during treatment.\n16. Willingness and able to use an acceptable method of contraception during the study and for at least 6 months after stopping the therapy.\n17. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n18. History and physical within 2 weeks prior to registration.\n19. Patients must provide study specific informed consent prior to study entry.\n\nExclusion Criteria:\n\n1. Unknown primary histology.\n2. Patients with rapid neurologic decline.\n3. Bony retropulsion causing neurologic abnormality.\n4. Non-ambulatory patients.\n5. Prior radiation to the involved site.\n6. Inability to have an MRI.\n7. Pre-existing or concomitant neurological problems not related directly to MESCC (e. g., neurologic deficits due to brain metastases).\n8. Very radiosensitive tumor histology (e.g., myeloma, seminoma, germ cell tumors, leukemia, and lymphoma).\n9. Patients with impaired decision-making capacity.",{"count":405,"type":23},10,[26],"The purpose of this study is to see if treating cancer with radiation therapy administered by the Varian Ethos system can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).",[409,410],"Metastatic Epidural Spinal Cord Compression","Spinal Cord Compression","2026-07-31",{"date":413,"type":35},"2026-08-04",{"date":415,"type":23},"2026-09-01",{"date":417,"type":23},"2028-09-01",{"name":41,"class":42},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":51,"minAge":314,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":43},"100390163","saber-study-for-selected-early-stage-breast-cancer-100390163","NCT04360330","SABER Study for Selected Early Stage Breast Cancer","Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Breast Radiotherapy (SABER) for Selected Early Stage Breast Cancer","SABER","Inclusion Criteria:\n\n1. Female, ≥ 50 years of age.\n2. Oncotype or MammaPrint diagnosis results are required prior to the start of treatment\n3. Histologically confirmed invasive breast cancer.\n4. Clinical stage T1N0M0.\n5. Receptor status: Estrogen-Receptor (ER)\u002FProgesterone-Receptor (PR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative.\n6. Unifocal breast cancer.\n7. Eastern Cooperative Oncology Group (ECOG) 0, 1.\n8. Ability to undergo MRI.\n9. Women of child-bearing potential (WOCBP) must agree to use adequate contraception or agree to undergo sexual abstinence prior to study entry and for the duration of study participation. WOCBP must have a negative serum or urine pregnancy test at time of enrollment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n10. Ability to understand the investigational nature, potential risks and benefits of the research study and willingness to sign the written informed consent and HIPAA document(s).\n\nExclusion Criteria:\n\n1. Patients without histologically confirmed invasive breast cancer.\n2. Patients without Oncotype or MammaPrint diagnosis results at the start of treatment.\n3. Patients with metastatic disease.\n4. ECOG 2, 3, 4.\n5. Patients that are unable to undergo MRI.\n6. Prior history of radiation to the chest.\n7. History of collagenous disease (systemic lupus erythematosus, scleroderma, dermatomyositis).\n8. Any serious medical or psychiatric illness\u002Fcondition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements\u002Ftreatment.\n9. Diagnosis of another primary malignancy within the last 5 years with the exception of non-melanoma skin cancer.\n10. Patients unable to consent, who are pregnant or nursing, or are prisoners.",{"count":257,"type":23},[26],"The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy\u002Faxillary surgery.",[431,432],"Breast Cancer","Early-stage Breast Cancer",[431,432],{"date":387,"type":35},{"date":436,"type":35},"2020-08-05",{"date":438,"type":23},"2029-05-31",{"name":41,"class":42},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":448,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":24,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":43},"100649491","artificially-intelligent-robot-control-100649491","NCT07738016","Artificially Intelligent Robot Control","Asthma Under Artificially Intelligent Robot (AIR) Control: Robotic Support for Pediatric Education","AIR","Inclusion Criteria for Caregivers or Parents:\n\n* The participant must be at least 18 years old.\n* The participant must be willing and able to participate.\n* The participant can read English or Spanish and is able to fill out survey instruments by themselves or with assistance.\n* The participant cares for a child age 4-11 with asthma.\n\nInclusion Criteria for Children:\n\n* The participant must be at least 4 years old - 11 years old with asthma.\n* The child can speak English or Spanish.\n* The participant must assent to participation.\n* The participant's guardian must have consented.\n\nExclusion Criteria for Caregivers or Parents:\n\n* The participant is younger than 18 years old.\n* The participant is unwilling to participate in the study.\n* The participant is unable to complete survey instruments.\n* The participant does not care for a child with asthma who is age 4-11.\n\nExclusion Criteria for Children:\n\n* The participant is younger than 4 years old, over 11 years old, or does not have asthma.\n* The child does not speak English or Spanish.\n* The participant is unwilling to participate in the study.\n* The participant's guardian did not consent.","4 Years",{"count":450,"type":23},80,[26],"The purpose of the study is to compare the impact of standard asthma education with the standard + Artificially Intelligent Robot (AIR) Control intervention.",[454,455,456],"Asthma in Children","Artificial Intelligence","Caregiver Burden","2026-07-30",{"date":387,"type":35},{"date":460,"type":23},"2026-09",{"date":462,"type":23},"2027-08-30",{"name":41,"class":42},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":471,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":43},"100650178","high-intensity-functional-training-hift-vs-moderate-intensity-continuous-training-mict-in-college-students-100650178","NCT07745270","High-Intensity Functional Training (HIFT) vs Moderate-Intensity Continuous Training (MICT) in College Students","The Effects of Interval Compared to Continuous Training on Physical Variables and Vascular Health in College Students: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 to 35 years.\n* Currently enrolled college or university student.\n* Able to provide written informed consent.\n* Able to attend baseline and post-intervention testing visits and participate in assigned intervention sessions.\n* Cleared for exercise participation based on the health screening form and investigator review.\n\nExclusion Criteria:\n\n* Known cardiovascular, metabolic, pulmonary, renal, neurological, musculoskeletal, or endocrine disorder that would make exercise unsafe or confound outcome measures.\n* Current pregnancy or planning pregnancy during the study period.\n* Current smoking, vaping nicotine products, or use of tobacco products.\n* Uncontrolled hypertension or resting blood pressure values that make exercise testing unsafe based on investigator judgment.\n* Use of medications known to substantially affect cardiovascular function, vascular tone, or exercise responses, unless approved by the PI.\n* Any injury, orthopedic limitation, or medical condition preventing safe participation in HIFT, MICT, or physical fitness testing.\n* Currently participating in structured high-intensity interval, functional, or endurance training more than two days per week during the previous three months.\n* Do not speak English.","35 Years",{"count":473,"type":23},90,[26],"The purpose of this study is to compare two types of exercise programs in college students: high-intensity functional training and moderate-intensity continuous training. The study evaluates whether these exercise programs improve body composition, physical fitness, and blood vessel health compared with a group that does not participate in exercise training. In addition, the study examines whether changes in body composition and physical fitness are associated with changes in blood vessel health.",[477],"Exercise","2026-07-29",{"date":413,"type":35},{"date":460,"type":23},{"date":482,"type":23},"2028-06",{"name":41,"class":42},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":24,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":43},"100461131","spectroscopic-mri-proton-therapy-and-avastin-for-recurrent-glioblastoma-100461131","NCT05284643","Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma","Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma","Inclusion Criteria:\n\nA. Recurrent glioblastoma (or variants such as gliosarcoma) based on one of the following criteria:\n\n1. An area of MRI enhancement consistent with glioblastoma outside of the initial high dose radiation field.\n2. Biopsy or resection proven recurrent glioblastoma.\n3. Progressive glioblastoma based on advanced imaging (brain positron emission tomography (PET), perfusion MRI, or clinical MR Spectroscopy)\n\nB. Pathology diagnosis of glioblastoma, or variants such as gliosarcoma, on initial and\u002For reresection by 2021 WHO glioblastoma criteria. Prior pathology reports or specimens can be reexamined and reclassified as glioblastoma based on current criteria.\n\nC. Total area of recurrence on T1 post-contrast MRI (including all nodules of likely tumor) have a linear maximum measurement of 6 cm or less.\n\nD. Patients must have received prior brain radiation therapy for glioma in conventional fractionation (1.8 - 2 Gy per fraction, total dose maximum 63 Gy).\n\nE. Patients must have completed prior brain radiation four to six months or more prior to study treatment for recurrent tumors that are at least half based within the high dose (\\> 46 Gy) radiation field.\n\n1. For \"marginal\" or \"out of field\" radiation failures where at least half of the enhancing disease is outside of the prior high dose radiation field but there is field overlap, patients must have completed prior radiation at least four months or more prior to study treatment.\n2. For \"in field\" radiation failures where at least half of the enhancing disease is within the prior high dose radiation field, patients must have completed prior radiation at least six months or more prior to study treatment.\n\nF. A minimum time must be elapsed from the administration of any prior anti-tumor or investigational agents to initiation of study treatments on this protocol as follows:\n\n1. 28 days or 5 half-lives, whichever is shorter, elapsed from the administration of any experimental agent prior to initiation of study treatment.\n2. 28 days elapsed from the administration of any prior cytotoxic agents except\n\ni. 14 days from vincristine and ≥ 21 days from procarbazine and Temozolomide (TMZ) prior to initiation of study treatment.\n\nG. Age at least 18.\n\nH. Patients must be able to have MRI scans.\n\nI. Patient must be able to provide written informed consent.\n\nJ. ECOG performance status 0-2.\n\nK. Life expectancy greater than 12 weeks at the discretion of the enrolling investigator.qa\n\nL. Female subjects should have a negative serum pregnancy test unless they confirm their menopausal status and\u002For have undergone previous hysterectomy and\u002For oophorectomy.\n\nM. Both men and women with childbearing potential should agree to use effective contraception for the duration of the treatment and for at least 6 months after the last treatment since medications that will be used can be harmful for the embryo. See contraception requirements, protocol section 4.16.\n\nN. Complete blood count (CBC)\u002Fdifferential within 21 days prior to registration with absolute neutrophil count at least 1500 cells\u002Fmm2, platelets at least 75,000 cells\u002Fmm2, and hemoglobin at least 9.0 g\u002Fdl (transfusion or other intervention to achieve Hgb of 9.0 or greater is acceptable).\n\nO. Liver function tests must demonstrate total bilirubin 2 mg\u002FdL or less, serum glutamic-oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) 2.5 times the upper limit of normal or less within 21 days prior to registration.\n\nP. Kidney function tests must indicate serum creatinine 1.8 mg\u002FdL or less within 21 days prior to registration and the following:\n\na. Urine protein: creatinine (UPC) ratio \\\u003C 1.0 within 14 days prior to registration OR urine dipstick for proteinuria ≤ 2+ (patients discovered to have \\> 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is \\\u003C1.0 to be eligible. If the UPC ratio is ≥ 1.0 then the patients should undergo a 24-hour urine collection and must demonstrate ≤1g of protein in 24 hours to be eligible).\n\ni. Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm. UPC ratio is calculated using one of the following formulas:\n\n1. \\[urine protein\\]\u002F\\[urine creatinine\\]: if both protein and creatinine are reported in mg\u002FdL\n2. \\[(urine protein) x0.088\\]\u002F\\[urine creatinine\\]: if urine creatinine is reported in mmol\u002FL\n\nQ. Patients on full-dose anticoagulants must meet both of the following criteria:\n\n1. No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\n2. In-range international normalized ratio (INR) (typically 2-3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, within 21 days prior to registration\n\nExclusion Criteria:\n\nA. Brain malignancies other than glioblastoma (or variants such as gliosarcoma) by WHO 2021 criteria (benign lesions like meningioma are allowed)\n\nB. Glioma that has not previously undergone standard first line therapies including a first course of radiation therapy.\n\nC. Glioma that has already undergone a second course of radiation therapy.\n\nD. Multi-focal disease (separate enhancing nodules across multiple brain lobes). Note: Multiple nodules in the same region are allowed as long as the total linear diameter is 6 cm or less.\n\nE. Patients who have had treatment with Bevacizumab in the past.\n\nF. Patients who will receive chemotherapy concurrent with study therapy other than bevacizumab.\n\nG. Patients with recurrent Glioblastoma (rGBM) based in the following anatomical regions known to have magnetic susceptibility or poor signal will be excluded: temporal lobe below the level of the floor of the third ventricle, orbitofrontal cortex, prefrontal cortex, medial frontal gyrus, brainstem, and cerebellum (these regions have known sMRI artifact).\n\nH. Pregnant or breastfeeding patients.\n\nI. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year. Non-invasive tumors are permissible (e.g., carcinoma in situ).\n\nJ. Severe active co-morbidities as follows:\n\n1. Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months prior to registration.\n2. Transmural myocardial infarction within the last 6 months prior to registration.\n3. History of stroke or transient ischemic attack within 6 months prior to registration.\n4. Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.\n5. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.\n6. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.\n7. Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects; note, however, that laboratory tests for liver function other than screening panel (Section 3.1) and coagulation parameters are not required for entry into this protocol.\n8. Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.\n\nK. Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.\n\nL. Prior allergic reaction to the study drug (Bevacizumab)\n\nM. Prior history of hypertensive crisis or hypertensive encephalopathy.\n\nN. History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration\n\nO. Gastrointestinal bleeding or any other hemorrhage\u002Fbleeding event Common Terminology Criteria for Adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration\n\nP. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)\n\nQ. Concurrent receipt of any other investigational agents",{"count":492,"type":23},96,[26],"The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Proton radiotherapy and bevacizumab (Avastin) are used to minimize the possible side effects of this approach.",[496],"Recurrent Glioblastoma",[498],"Brain Cancer","2026-07-27",{"date":478,"type":35},{"date":502,"type":35},"2022-09-30",{"date":504,"type":23},"2029-09-30",{"name":41,"class":42},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":17,"sex":18,"minAge":513,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":24,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":43},"100626515","guardant-shield-colorectal-cancer-screening-100626515","NCT07436637","Guardant Shield Colorectal Cancer Screening","Using Guardant ShieldTM to Facilitate Colorectal Cancer Screening in Under-screened Individuals in a Diverse Patient Population","Inclusion Criteria:\n\n* Adults 45 - 85 years of age at average risk and able to provide informed consent.\n* Patients overdue for a screening colonoscopy or stool-based test that was ordered by their University of Miami (UM) clinician.\n\nExclusion Criteria:\n\n* Impaired decision-making capability\u002Funable to provide informed consent.\n* Patients with high-risk conditions:\n\n  * Personal history of colorectal cancer (CRC), adenomas, or other cancers\n  * Those who had a positive result on another CRC screening method within the last six months, an abnormal stool test that found blood in your stool within the last 12 months, or abnormal Cologuard (FIT-DNA Test) in the last 3 years\n  * Those with Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn's disease\n  * Those who have a family history of colorectal cancer (in a parent, brother, sister, or child)\n  * Genetic predisposition requiring more frequent screening (such as Lynch syndrome, IBD, history of colectomy, etc.)\n  * Symptoms like rectal bleeding, weight loss, or other signs for which your doctor ordered a colonoscopy - not simply as a screening tool","45 Years","85 Years",{"count":516,"type":23},500,[26],"The purpose of this research is to identify individuals overdue for colon cancer screening and send them a reminder to complete their screening, which includes standard of care colonoscopy or stool-based testing. The investigators are randomizing patients (like a flip of a coin) to either receive the standard reminder by mail\u002Femail or to receive the standard reminder and have the option to provide a blood sample for screening (ShieldTM by Guardant).",[520],"Colorectal Cancer","2026-07-23",{"date":499,"type":35},{"date":349,"type":35},{"date":525,"type":23},"2027-04-01",{"name":41,"class":42},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":24,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":43},"100624710","phase-2-autologous-serum-tears-with-hyaluronate-vs-balanced-salt-solution-for-moderate-to-severe-dry-eye-100624710","NCT07413172","Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye","The Effect of Autologous Serum Tears Diluted to 50% With 0.2% Sodium Hyaluronate-Containing Preservative-Free Artificial Tears Versus Autologous Serum Tears Diluted to 50% With Balanced Salt Solution in Patients With Moderate-to-Severe Dry Eye Disease: A Prospective, Double-Blind, Randomized, Controlled, Contralateral-Eye Study","Inclusion Criteria:\n\n* Age ≥ 18 years old\n\n  * Formal diagnosis of one of the following conditions associated with aqueous-deficient dry eye disease: Sjögren's syndrome (primary or secondary), Mucous membrane pemphigoid, Graft-versus-host disease, Stevens-Johnson syndrome, Post-radiation lacrimal gland aqueous deficiency, or Neurotrophic keratitis\n  * Moderate-to-severe Dry Eye Disease (DED) symptoms for at least 6 months prior to study enrollment.\n  * OSDI score ≥ 25 and\u002For and OSDI-6 score \\> 6 at the screening visit\n  * Presence of at least two of the following clinical signs in the same eye, at the screening visit: Anesthetized Schirmer's test score 7 ≤ mm at 5 minutes, Tear Break up Time (TBUT) ≤ 7 seconds, Corneal fluorescein staining score ≥ 4 (maximum 15) as assessed by the National Eye Institute (NEI) grading scale 25, or Conjunctival lissamine green staining ≥ 3 (maximum 18) as assessed by the NEI grading scale\n  * Desire to use autologous serum tears at least twice daily in the 2 weeks prior to screening visit.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old.\n\n  * Cognitive impairment or psychiatric condition that precludes informed consent or the ability to comply with study procedures.\n  * Any clinical condition identified at screening that, in the opinion of the treating physician, is clinically significant and would contraindicate safe participation in the study.\n  * Any condition or treatment known to affect the signs and symptoms of DED, including pregnancy, regular use of contact lenses, recent diagnosis of ocular allergy, infection, or inflammation, or recent ocular surgery within 6 months.\n  * Patients with stable ocular surface disease or neurotrophic keratitis secondary to prior ocular surgery, chronic glaucoma therapy, or eyelid abnormalities may be included.",{"count":535,"type":23},20,[297],"This study aims to find out whether adding sodium hyaluronate, a moisturizing ingredient commonly found in artificial tears, makes autologous serum eye drops more effective for treating moderate-to-severe dry eye disease. Each participant will use one version of the drops in one eye and the standard version in the other eye. The goal is to see if the new combination provides better relief, comfort, and eye surface healing compared to the traditional formulation.",[539,540,541],"Dry Eye","Eye Diseases","Eyes Dry Chronic",{"date":543,"type":35},"2026-07-24",{"date":545,"type":35},"2026-07-21",{"date":547,"type":23},"2028-07",{"name":41,"class":42},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":43},"100619134","facial-papules-in-frontal-fibrosing-alopecia-ffa-100619134","NCT07340671","Facial Papules in Frontal Fibrosing Alopecia (FFA)","Evaluating the Efficacy of the 1726nm Laser for the Treatment of Facial Papules in Frontal Fibrosing Alopecia (FFA)","Inclusion Criteria:\n\n* Female or Male\n* Fitzpatrick Skin Types I-VI\n* At least 18 years of age\n* Has clinically diagnosed FFA with facial papules.\n* Subject must be able to read, speak, and understand English or Spanish and sign the Informed Consent Form.\n* Willing and able to adhere to the treatment and follow-up schedule and pre\u002Fpost-treatment care instructions.\n* No contraindication to laser therapy.\n* Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes.\n* Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study.\n* Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.\n\nExclusion Criteria:\n\n* Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.\n* Prior treatment to the target area within 3 months of study participating including chemical peel, dermabrassion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.\n* Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study.\n* Systemic use of retinoid, such as isotretinoin, within 3 months of study participation.\n* Still healing from another treatment in the target area according to investigator's discretion.\n* History of malignant tumors in the target area.\n* Pregnant and\u002For breastfeeding or planning to become pregnant during the study.\n* History of diagnosed immunosuppression\u002Fimmune deficiency or currently using immunosuppressive medications.\n* History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.\n* Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.\n* History of disease stimulated by heat, such as recurrent herpes simplex and\u002For herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.\n* History of radiation to the target area, currently undergoing treatment for skin cancer in the target area, or undergoing systemic chemotherapy for the treatment of cancer.\n* History of diagnosed pigmentary disorders (including vitiligo) in the target area.\n* Excessively tanned in the treatment area or unable\u002Funlikely to refrain from tanning in the target area during the study.\n* History of keloids or hypertrophic scarring.\n* Prisoners\n* As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study, might interfere with patient's participation in the full study protocol, or might interfere with the diagnosis or assessment of facial papules.",{"count":405,"type":23},[26],"The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of facial papules in frontal fibrosing alopecia (FFA).",[560],"Frontal Fibrosing Alopecia",{"date":543,"type":35},{"date":563,"type":35},"2026-04-28",{"date":565,"type":23},"2027-04-28",{"name":41,"class":42},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":24,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":43},"100577701","rosacea-radiofrequency-microneedling-100577701","NCT06801717","Rosacea Radiofrequency Microneedling","Split-Face Comparison of 532nm Potassium Titanyl Phosphate (KTP) Laser Treatment Versus Radiofrequency Microneedling in Combination With 532 KTP Laser for Erythematotelangiectatic or Papulopustular Rosacea","Inclusion Criteria:\n\n1. Male or female adult (\\>18yo) subjects in general good health\n2. Clinical and\u002For histologic diagnosis of erythematotelangiectatic or papulopustular rosacea.\n3. Subject is able to understand and sign informed consent\n4. Subject is able to complete the study and comply with study procedures\n\nExclusion Criteria:\n\n1. Patients currently utilizing oxymetazoline or brimonidine.\n2. Presence of dermatoses that might interfere with diagnosis as determined by a study investigator\n3. Presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum\n4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment\n5. History of poor wound healing or blood-clotting abnormality\n6. History of keloid formation or hypertrophic scarring\n7. Hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional.\n8. Prisoners",{"count":535,"type":23},[26],"There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.",[578,579],"Rosacea, Papulopustular","Rosacea, Erythematotelangiectatic",{"date":543,"type":35},{"date":582,"type":35},"2024-11-01",{"date":584,"type":23},"2027-07-01",{"name":41,"class":42},""]